4.2 Article

Recommended Screening and Preventive Practices for Long-Term Survivors after Hematopoietic Cell Transplantation

Journal

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Volume 18, Issue 3, Pages 348-371

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2011.12.519

Keywords

Hematopoietic cell transplantation; Allogeneic; Autologous; Late complications; Screening; Prevention

Funding

  1. Public Health Service from National Cancer Institute (NCI) [U24-CA76518]
  2. National Heart, Lung and Blood Institute (NEILBI)
  3. National Institute of Allergy and Infectious Diseases (NIAID)
  4. NHLBI [5U-01HL069294]
  5. NCI
  6. Office of Naval Research [N00014-06-1-0704, N00014-08-1-0058]
  7. AABB
  8. Allos, Inc.
  9. Amgen, Inc.
  10. Health Resources and Services Administration (HRSA/DHHS) [HHSH234200637015C]
  11. Grants-in-Aid for Scientific Research [23791077] Funding Source: KAKEN

Ask authors/readers for more resources

Advances in hematopoietic cell transplantation (HCT) technology and supportive care techniques have led to improvements in long-term survival after HCT. Emerging indications for transplantation, introduction of newer graft sources (eg, umbilical cord blood) and transplantation of older patients using less intense conditioning regimens have also contributed to an increase in the number of HCT survivors. These survivors are at risk for developing late complications secondary to pre-, peri-, and posttransplantation exposures and risk factors. Guidelines for screening and preventive practices for HCT survivors were published in 2006. An international group of transplantation experts was convened in 2011 to review contemporary literature and update the recommendations while considering the changing practice of transplantation and international applicability of these guidelines. This review provides the updated recommendations for screening and preventive practices for pediatric and adult survivors of autologous and allogeneic HCT. Biol Blood Marrow Transplant 18: 348-371 (2012) (C) 2012 Published by Elsevier Inc. on behalf of the American Society for Blood and Marrow Transplantation

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available